Calamos Advisors
CLBT icon

Calamos Advisors’s Cellebrite CLBT Stock Holding History

Calamos Advisors’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38,642
Closed -$751K – 938
2025
Q1 		$751K Sell
38,642
-68,337
-64% -$1.44M ﹤0.01% 681
2024
Q4 		$2.36M Buy
106,979
+71,120
+198% +$1.37M 0.01% 593
2024
Q3 		$604K Buy
+35,859
New +$532K ﹤0.01% 702

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Calamos Advisors's CLBT Position: Q2 2025 in Review

Calamos Advisors sold out of Cellebrite (CLBT) in Q2 2025, closing a stake of 38,642 shares — an estimated $751K sold.

Calamos Advisors first reported a position in CLBT in Q3 2024 and held it in 3 quarters. The position peaked at $2.36M in Q4 2024. 209 funds tracked by Wall St. Rank hold CLBT as of Q2 2025.

  • Calamos Advisors reported no remaining Cellebrite position as of Q2 2025 after selling out during the quarter.
  • Calamos Advisors sold 38,642 Cellebrite shares in Q2 2025, an estimated $751K.
  • Calamos Advisors first reported a position in Cellebrite in Q3 2024 and held it in 3 quarters.
  • Calamos Advisors's Cellebrite position peaked at $2.36M in Q4 2024.
  • 209 funds tracked by Wall St. Rank held Cellebrite as of Q2 2025.

Based on Calamos Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.